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The hypothesis is offered predicting that Gaucher patients could be treated with a drug that slows the synthesis of 
glucosylceramide, the lipid that accumulates in this disorder. The present therapeutic approach involves augmenting 
the defective enzyme, glucosylceramide /3-glucosidase, with exogenous /3-glucosidase isolated from human tissue. 
This spectacularly expensive mode of treatment should be replaceable with a suitable enzyme inhibitor that simply 
slows tbrmation of the lipid and matches the rate of synthesis with the rate of the defective, slowly working /3- 
glucosidase. Several drugs that possess this ability are available, the best known of which is 1-phenyl-2- 
decanoylamino-3-morpholino-l-propanol (PDMP), a designer inhibitor that resembles the synthase's substrate and 
product. PDMP has been found to be effective in mice, rats, fish, and a wide variety of cultured cells. Its use, at 
suitable dosages, seems to be harmless, although long-term tests have not been made. The lack of suitable animal 
models of Gaucher disease has made it difficult to test the hypothesis adequately, but PDMP does rapidly lower the 
levels of glucosylceramide in normal animal tissues and the animals evidently do well with the lowered levels of 
glucosylceramide and its more complex glycolipid metabolites. 
Keywords: glucosylceramidase insufficiency, Gaucher disease chemotherapy, glucosytceramide synthase inhibition, 
PDMP (1-phenyl-2-decanoylamino-3 -morpholino- 1-propanol) 
Abbreviations: PDMP, 1-phenyl-2-decanoylamino-3-morpholino-l-propanol; GlcCer, glucosylceramide; i.p., 
intraperitoneal. 
Introduction 
Most Gaucher patients possess a modest level of  
glucosylceramide /3-glucosidase, as much as 40% of the 
normal level, so their disorder develops slowly. The 
slowness of  development is evidently due to a. small 
imbalance between the rate of  glucosylceramide (GlcCer) 
synthesis and the rate of  its hydrolysis. This results in the 
gradual accumulation of  GlcCer. The clinical symptoms 
seem to arise mainly from accumulated macrophages, 
which apparently form in response to the problem of  
disposing of the GlcCer derived from catabolizing red and 
white blood cells. Injection of  chemically modified ]3- 
glucosidase ('Ceredase') is the present treatment modality, 
since it seeks out the cells that store or normally 
catabolize the lipid. However it must be injected 
throughout the life of  the patient and constitutes an 
extraordinarily expensive, albeit effective, way to treat 
these patients. The hypothesis developed in this paper is 
that slowing the synthesis of  GlcCer with a suitable 
inhibitor will allow the patient to form red and white 
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blood cells that have a lowered content of  GlcCer. The 
GlcCer in these cells should then be able to undergo 
hydrolysis at an adequate rate, despite the patient's low 
level of  glucosidase. In addition, the glycolipid presently 
stored before treatment is begun, will either be utilized for 
normal cell functioning or hydrolysed. The storage cells 
themselves probably also synthesize GlcCer for their own 
needs; this must add to the burden but could be slowed 
with a synthase inhibitor. 
White dells synthesize GlcCer, probably throughout 
their life span. Thus the administration of a synthase 
inhibitor would rapidly lower the content of GlcCer in 
circulating cells, producing a rapid reduction in the rate 
of  glycolipid deposition. 
By now, - 5 0  papers have been published describing 
the effectiveness of D-threo-l-phenyl-2-decanoylamino-3- 
morpholino-l-propanol (PDMP) and related compounds 
as inhibitors of GlcCer synthase. The compounds are 
active at the micromolar level in mice, rats, fish, and a 
wide variety of  cultured cells (canine and human kidney, 
human turnouts, C3H murine splenocytes, IL2-dependent 
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CTLL, rabbit skin fibroblasts, murine Lewis lung 
carcinoma, A431 human epidermoid carcinoma, human 
and mouse embryonal carcinoma, human intestinal 
epithelial, NIH 3T3, B16 melanoma, multiple drug 
resistant and others). PDMP is easy to synthesize so it 
should be a relatively economical substitute or adjuvant 
for Ceredase. It is currently available from four 
companies for non-human use. This paper presents some 
of the evidence supporting the proposed rationale. 
Related, newer drugs, more effective in cultured cell 
studies, are also described. 
Mode of action 
PDMP was designed to simulate the structures of 
ceramide (the lipoidal precursor of GlcCer) and GlcCer 
itself. It apparently acts at the enzyme's active site, as well 
as on a similar binding site [1]. It is not a covalently 
inactivating inhibitor, but some evidence [2] points to 
partial metabolic conversion to such a substance. Its use in 
mice leads to some elevation in GlcCer glucosidase [3], an 
effect which should enhance its usefulness, assuming such 
an effect can be obtained with the defective glucosidase. 
The optical enantiomer of PDMP, the L-threo form, 
does not inhibit GlcCer synthase, but its use in some 
cultured cells has led to a reduction in glycotipid levels. 
Thus, for reasons of economy, the DL-racemic mixture 
may be satisfactory in Gaucher patients. It has been used 
in some of the published studies of PDMP. 
rapid decrease shows that GlcCer undergoes rapid 
metabolism in normal kidney, possibly in all organs. In 
mice injected twice a day for 4 d, a similar decrease in 
kidney GlcCer was found. 
Coadministration of L-cycloserine augmented the effect 
of PDMP in the latter experiment. (L-Cycloserine is not 
the antitubercular drug, D-cycloserine.) The combination 
lowered the level of the glycolipid by 50%. L-Cycloserine 
is an inhibitor of sphingosine synthesis, leading to a 
depletion of its product, ceramide [4]. Ceramide com- 
petes against PDMP in binding to the synthase [1]. Thus 
cycloserine potentiates the effectiveness of PDMP in two 
ways and might prove a useful adjuvant in Gaucher 
patients. 
When PDMP was added to the growth medium of 
embryonic medaka, a tiny fieshwater fish, the embryos 
hatched normally by 10d [5]. The treated fish were 
morphologically normal. This long exposure to 20/xM 
PDMP resulted in a drastic loss of the ability to 
synthesize GlcCer and its higher metabolites from 
[3H]galactose and a virtually complete loss of the 
reactivity of several glycolipids with specific antibodies. 
Since nearly all glycolipids are derived from GlcCer, 
blocking the synthesis of GlcCer leads to catabolic 
depletion of all these compounds. 
After hatching, the fish were raised in normal medium 
for 2 weeks, during which time there was restoration of 
the ability to make glycolipids. The PDMP-treated fish 
exhibited normal swimming, feeding, responses to light 
and obstacle avoidance. 
Metabolism of PDMP 
Tests with labelled PDMP in mice have shown that it is 
largely destroyed and then excreted within - 3  h after a 
single dose i.p. [2]. The destruction is evidently due to a 
cytochrome P450, since it can be slowed or blocked by 
coadministration of either of two P450 inhibitors posses- 
sing low toxicity, cimetidine and piperonyt butoxide. Most 
of the animal studies were done without the aid of a P450 
inhibitor, so a high dose was necessary to produce a 
lasting effect. The labelled drug exhibited good penetra- 
tion of all organs tested and should thus be effective 
throughout the patient's body. Preliminary tests indicated 
that PDMP readily enters the body when mixed with food, 
thus obviating the need for injections. 
Effectiveness in lowering GlcCer levels 
A high but tolerable dose of DL-PDMP (100 mgkg-t) ,  
injected i.p. into normal mice, produced a 35% loss of 
GlcCer in kidney (as well as a 15% loss of the next higher 
metabolite, lactosylceramide) within just 5 h [3]. This 
Is PDMP toxic? 
An experiment with normal young mice treated with high 
doses of PDMP, given in 12 daily injections, and analysed 
40 h after the last injection, showed that the body, liver, 
brain, and spleen weights were normal, although the 
kidneys were 11% smaller (statistically significant) [6]. 
Initially there was a loss in body weight, but the treated 
mice caught up with the saline controls. Blood cell counts 
of the RBC, monocytes, lymphocytes, eosinophiles, and 
neutrophiles revealed no abnormalities. 
The size of kidneys in mice seems to be particularly 
sensitive to the level of GlcCer. Injecting testosterone 
into young mice rapidly raised the level of GlcCer 
synthase, lowered the level of GlcCer /3-glucosidase, and 
accelerated the rate of kidney growth [7]. This finding 
suggests that the enlargement of liver and spleen 
characteristic of Gaucher disease reflects, in part, a 
proliferative action of GlcCer. Intraperitoneal injection of 
GlcCer into mice did indeed result in deposition in the 
liver and rapid growth of the liver [8]. (Predictably, these 
effects disappeared in a few days because the glucosidase 
was not defective in these animals.) 
Chemical treatment of Gaucher disease 
The shrinking action of PDMP was utilized in diabetic 
rats, which - like human diabetics - develop enlarged 
kidneys. The PDMP treatment brought the kidney size 
back to normal despite the high level of glucose [9]. 
Normal kidney function was retained. Curiously, Gaucher 
patients do not seem to show kidney abnormalities or 
deposition of GlcCer in their kidneys. Perhaps their 
kidneys excrete accumulated GlcCer. 
In other tests, in which mice were first inoculated with 
Ehrlich ascites carcinoma cells, PDMP given for 5 or 10 
days greatly prolonged the survival time for many of the 
mice and apparently produced permanent cures in - 3 0 %  
of the animals [6]. Control inoculated mice all died 
within - 2 4  days. When the surviving mice, still frisky 
after 135 days, were reinoculated with new ascites cells, 
the tumours failed to develop. Evidently the mice had 
developed protective antibodies against the tumour cells. 
This is suggestive (but incomplete) evidence that the drug 
does not harm the inunune system; if anything, it 
augments the ability of the immune system to attack 
turnout cells. These observations are of special impor- 
tance to Gaucher patients, who have a tendency to 
develop some forms of cancer [10], possibly due to a 
proliferative action of GlcCer. 
The medaka fish mentioned above seemed to exhibit 
no toxic reaction to PDMP despite their great depletion 
of GlcCer. In addition, B16 melanoma cells cultured in 
--20/zM PDMP also lost most of their GlcCer, yet 
recovered their synthetic abilities when placed in a drug- 
free medium [11]. 
The lack of toxicity in cells and organisms depleted of 
their normal level of GlcCer is surprising, considering the 
almost ubiquitous distribution of glycolipids. In the case 
of the laboratory cells, mice, rats, and fish, the 
environment was of course optimal and unstressful. From 
the many reports of glycolipid functions in cell binding, 
growth, and differentiation, one would guess that mam- 
mals living in the real world would be in a precarious 
state if they were too depleted of their glycolipids. On 
the other hand, chronic depletion might protect us from 
attack by many viruses and bacteria, which are known to 
bind to specific GlcCer-derived glycolipids. Such protec- 
tive action by PDMP against binding of culm.red human 
kidney and intestinal cells to E. coli has been demon- 
strated [12]. 
Side-effects of PDMP 
PDMP and related inhibitors can, at sufficiently high 
concentrations, drastically slow growth and proliferation. 
This is apparently the result of a process causing 
accumulation of GlcCer's precursor, ceramide [13]. This 
substance has recently come to be considered a part of cell 
signalling events leading to cell death. However the 
inhibitors do not produce ceramide accumulation at low 
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Figure 1. (a) Structure of D-threo-PDMP; (b) pyrrolidino deox- 
yceramide. 
concentrations, yet readily block GlcCer synthesis. The 
very effective aliphatic inhibitor, pyrrolidino deoxycer- 
amide (Fig. lb), does not cause ceramide accumulation or 
growth inhibition even at higher concentrations, so it 
might be safer than PDMP. 
Soon after injection of high doses into mice and rats, 
behavioural symptoms were seen, subsiding after about 
15 rain. Including PDMP in mouse feed produced no 
observable reactions. Of course bolus type doses would 
be unnecessary in human subjects. 
Mice injected with DL-PDMP nine times were found 
to lose 23% of their kidney ceramide level and 31% of 
their kidney GlcCer, while sphingomyelin was unaffected 
[3]. In another experiment, using two injections, mice 
developed elevated levels in the specific activity of 
GlcCer glucosidase (+25%), GalCer galactosidase 
(+34%), and sphingomyelinase (+33%). /3-Glucuronidase 
was slightly reduced. 
Cultured cells have been analysed in depth and 
changes were found in a variety of cell components 
[13-15]. It is interesting that ceramide levels went up (at 
high dosage levels), in contradiction to the decrease seen 
in intact mouse kidney. It seems likely that some of the 
changes seen in cultured cells do not occur in intact 
animals, owing to compensatory systems. However, like 
any other drug, PDMP could exhibit surprises for treated 
patients. 
Other potentially useful mediators of  GlcCer 
metabolism 
A single injection of the tranquilizer, chlorpromazine, into 
mice was found to lower GlcCer synthase specific activity 
in liver substantially ( -47%)  in only 3 h, while producing 
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an increase in ceramide concentration (+25%) [16]. The 
mechanism for the effect is not known but the possible 
application to Gaucher disease warrants further study. 
A search for activators of Gau~her glucocerebrosidase 
might prove useful. The enzyme in the brain of a 
Gaucher patient was tripled in activity, in vitro, by 
gluconoyl hydrazine [17]. A series of syntheses of related 
structures ought to be attempted. 
PDMP homologues made with longer chain fatty acids 
(PDMP contains the decanoic acid moiety) have been 
found to inhibit GlcCer synthase in vitro more effectively 
than PDMP. Preliminary tests of the longer chain 
compounds in mice inoculated with Ehrlich ascites cells 
indicated it was more effective in curing the mice [6]. 
Recent work has shown that replacing the morpholine 
moiety with other cyclic amines enhances the effective- 
ness against GlcCer synthase and tumour cell growth 
[13]. Some aliphatic analogues of PDMP have also 
proved highly effective as synthase inhibitors. As little as 
0.1 /.LM inhibitor with cultured cells produced distinct 
depletion of GlcCer in 24 h. It seems likely that we can 
produce an effective depletion of glycolipids in Gaucher 
patients with just small doses of these compounds. Here 
too further synthetic efforts could furnish even more 
effective drugs. 
Recently, a cationic glycolipid with only a short 
aliphatic chain (N-butyl-deoxynojirimicin) was found to 
be a good inhibitor of GlcCer symhase. The authors 
proposed that this, like PDMR might be useful for 
Gaucher patients. An isomeric form of this substance has 
been reported to be more effective, while avoiding 
inhibition of glucosidases. [18]. Replacing the rather 
nonspecific butyl group with a ceramide-like group might 
greatly enhance its inhibitory activity. 
A study of GlcCer glucosidase [19] has revealed that 
the enzyme has the ability to utilize various alcohols 
instead of water (i.e. it can carry out transglucosylation). 
It seems possible that ingesting a suitable glucose 
acceptor would allow even a Gaucher patient's enzyme 
to convert GlcCer to a more soluble, more easily excreted 
glucoside. This approach looks useful and warrants 
further study. 
Some normal body components are involved in the 
action of glucosidase: saposin C (a small protein that acts 
as a cofactor in the action of the enzyme) and 
phosphatidylserine, which has a similar, coordinate 
function. Supplementation by these substances or syn- 
thetic compounds related in structure might prove very 
beneficial. We have shown that mice preloaded with 
GlcCer and treated with the glucosidase inhibitor, 
conduritol B epoxide ('temporary Gaucher mice'), can 
be restored to normalcy more rapidly if injected with 
phosphatidylserine [20]. 
Cultured cells absorb glucosidase much better if the 
enzyme is first complexed with saposin C and phospha- 
tidylserine [2t]. This characteristic might be helpful with 
Ceredase for lowering the required dosage. 
Possible complications 
(a) The proposed hypothesis assumes that our GlcCer 
synthase inhibitor acts on circulating blood cells and the 
cells that form the blood elements. These are the cells that 
furnish much of the burden of GlcCer hydrolysis on the 
liver and spleen. Many types of cells are sensitive to these 
compounds - mammalian and piscine, in organ masses 
and separate, in culture dishes. Thus it seems very 
plausible to expect that the blood cells are also sensitive. 
The same assumption applies to the macrophages that 
store, and presumably also synthesize, GlcCer. 
(b) Perhaps a cell type in the body exists that is 
exceptionally sensitive to the synthase inhibitors. Kidney 
cells do seem to be more sensitive but not toxically so. 
Multiple drug resistant cells are somewhat more sensitive 
to synthase inhibitors [22-] but this is hardly a negative 
property. Obviously there is a need for long-term toxicity 
testing in animals. 
(c) Perhaps a patient would develop tolerance toward 
the synthase inhibitors. This is always a potential problem 
with drugs that must be used over a long period. 
Rosenwald and Pagano were able to develop a strain of 
CHO cells that required double the dose of PDMP to 
achieve the same effect [22]. Only tests in human 
subjects will tell us if  this is a realistic problem. 
(d) The toxicity of the proposed adjuvant drugs (e.g. L- 
cycloserine) also needs more study. An advantage of 
using a combination of drugs is that the dose of each 
could be lowered, compared with single drug use. The 
combinations could include Ceredase at a more econom- 
ical level. 
(e) The glycolipid-depleted blood cells in inhibitor- 
treated Gaucher patients might not function well; perhaps 
their life spans would be shortened. However mice 
injected with high doses of PDMP for 12 days seemed 
perfectly healthy. 
(f) The hypothesis presented here would not be useful 
for the infantile, neuronopathic form of Gaucher disease 
since there is so little functioning glucosidase in these 
patients. 
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